Equities

Golden Valley Development Inc

GVDI:PKC

Golden Valley Development Inc

Actions
  • Price (USD)0.017
  • Today's Change0.00 / 0.00%
  • Shares traded1.30k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 04 2024 20:49 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Golden Valley Development, Inc. is a development-stage company. The Company operates as a holding company. The Company is engaged in various business activities. The Company, through its subsidiary, Digit-Pro, develops patents, and manufactures and distributes patented and patentable products. Its products include Percuguard and Cutstop, which are intended for use in the healthcare and hospitality services industries. The Company, through its subsidiary, Sports Media Production, Inc., focuses on developing sports, media and other entertainment properties. Its media sports and entertainment products and services will be augmented with technology, enabling social networking technology to manage interaction with fans on various topics of interest. The Company, its subsidiary, eWaste Exchange, will provide Web-based services to the forward and reverse logistics, including electronic waste, and logistics to a range of industries and organizations, such as retail and hospitality.

  • Revenue in USD (TTM)0.00
  • Net income in USD-92.53k
  • Incorporated2004
  • Employees0.00
  • Location
    Golden Valley Development Inc1200 Truxton Avenue #130BAKERSFIELD 93301-4643United StatesUSA
  • Phone+1 (661) 327-0067
  • Websitehttps://goldenvalleydev.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sigyn Therapeutics Inc0.00-3.70m9.15m5.00---------3.08-3.080.00-2.910.00----0.00-1,085.72-493.15-----------10,223.960.0247-2.09---------41.51------
ALR Technologies Inc9.49k-8.00m9.21m6.00------970.95-0.0147-0.01470.00002-0.04760.0358----1,581.67-3,015.28-12,861.64----62.49---84,283.24-406,011.30---0.8626---------42.72------
Applied DNA Sciences Inc3.40m-7.52m9.64m53.00--0.1587--2.84-11.86-11.862.181.200.20926.835.6864,114.15-45.51-88.57-55.20-121.9125.0444.35-217.48-113.263.76--0.00---26.4327.92-18.73--33.80--
T2 Biosystems Inc7.16m-48.26m10.14m113.00------1.41-10.70-10.701.09-0.33910.24352.825.4163,398.23-164.01-106.01---253.03-86.96-12.60-673.67-317.930.359-12.442.00---67.75-7.2919.66---20.19--
Scientific Industries Inc10.45m-7.76m10.50m63.00--0.8992--1.00-0.9231-0.92311.171.110.73431.139.08165,942.90-54.50---62.11--45.41---74.22--3.15--0.00--------------
REMSleep Holdings Inc144.88k-1.81m10.64m6.00--18.50--73.42-0.0012-0.00120.00010.00040.081.694.75---99.82-152.40-122.32-317.98-491.08---1,246.94-2,317.521.47-43.580.1207---36.48--12.13--28.26--
QT Imaging Holdings Inc0.00-4.02m10.94m----0.5029-----0.3999-0.39990.001.010.00-------12.32---16.60--------------0.3042-------45.07------
PetVivo Holdings Inc975.28k-10.11m11.19m20.00--13.43--11.48-0.6705-0.67050.0620.04170.32570.40516.3748,764.00-337.63-230.77-589.09-467.9983.6066.21-1,036.50-1,501.440.455-1,075.050.0221--5.62---25.67--23.91--
SeaStar Medical Holding Corp0.00-33.23m11.39m12.00---------21.41-21.410.00-2.140.00----0.00-1,145.80-----------------9.51---------115.19------
Innovative Eyewear Inc1.53m-7.86m11.50m11.00--1.52--7.52-11.01-11.012.054.810.17791.9715.91139,070.90-91.45---96.06---2.46---514.10--12.85--0.00--74.67---17.28------
PAVmed Inc3.83m-67.35m11.55m107.00------3.02-8.17-8.170.4595-7.740.0823--29.4535,785.05-155.93-154.56---1,152.82-77.59---1,895.64-8,764.890.5529-8.161.74--550.40--25.76--55.51--
Golden Valley Development Inc0.00-92.53k11.63m0.00---------11.17-11.170.00-0.02110.00-------7,710.83-------------3,073.27---3.96--------45.48------
Guided Therapeutics Inc38.00k-2.39m11.68m4.00------307.30-0.0444-0.04440.0007-0.08290.02110.03658.449,500.00-120.81-136.13----42.1129.39-5,721.05-3,666.670.0679-7.58----653.8511.4524.40------
BioRegenx Inc1.29m-4.28m12.24m10.00--0.8609--9.47-0.0053-0.00530.00230.01490.1438----129,234.00-47.59---58.94--66.76---331.00--0.0533-28.810.1284---47.25---629.37------
Autonomix Medical Inc-100.00bn-100.00bn12.88m5.00--2.03----------5.50----------------------------0.1647-------674.99------
STRATA Skin Sciences Inc32.73m-8.31m12.90m99.00--1.14--0.394-2.37-2.379.352.710.69063.477.81330,606.10-17.54-11.48-24.26-16.5554.3061.28-25.40-17.700.9176-2.690.6141---7.752.24-95.17--23.29--
Data as of Nov 04 2024. Currency figures normalised to Golden Valley Development Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.